Hims to cut 4% of workforce amid ban on weight-loss drug copies
Telehealth platform Hims & Hers will cut about 4% of its workforce, as it adjusts to a U.S. ban on manufacturing mass copies of the weight-loss drug Wegovy.
You are not logged in so some information on this page has been withheld. To see more, please log in.
Telehealth
since
auto-detected in 14 stories
4 days ago
90 days ago
Teladoc, LifeMD tie up with Lilly's pharmacy partner to offer Zepbound
found
Telehealth firms Teladoc and LifeMD said they signed an agreement with Eli Lilly's pharmacy partner to offer patients the weight-loss drug, Zepbound.
page 1 of 1